Vorasidenib
Orphan DrugFDA Approved
Description
Vorasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-1 and 2 (IDH1/2) enzymes. It is indicated for adult patients with IDH1- or IDH2-mutant low-grade glioma.
Indications & Therapeutic Use
Low-grade glioma
Linked Diseases:
oligodendroglioma
C71D009837
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Vorasidenib
| Generic Name | Vorasidenib |
| Brands | 1 brand available |
| Active Ingredient | Vorasidenib |
| Drug Class | Low-grade glioma |
| Manufacturer | Servier Pharmaceuticals |
| Dosage Forms | Tablet |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT04164901 |
| Countries | 1 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes